The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy
Authors
Keywords
-
Journal
Cellular & Molecular Immunology
Volume 19, Issue 2, Pages 192-209
Publisher
Springer Science and Business Media LLC
Online
2022-01-18
DOI
10.1038/s41423-021-00786-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells
- (2021) Caleb R. Glassman et al. CELL
- Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10
- (2021) Robert A. Saxton et al. SCIENCE
- Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor
- (2021) Marie Robert et al. Cellular & Molecular Immunology
- MDNA11 is a long-acting IL-2 superkine that potentiates durable immune response in mouse tumor models and non-human primates.
- (2021) Minh D. To et al. JOURNAL OF CLINICAL ONCOLOGY
- Three paralogous clusters of the miR-17~92 family of microRNAs restrain IL-12-mediated immune defense
- (2020) Xiang Zhang et al. Cellular & Molecular Immunology
- Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade
- (2020) Shinsuke Nakao et al. Science Translational Medicine
- Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
- (2020) Heliang Li et al. Cellular & Molecular Immunology
- The transcription factor RelB restrains group 2 innate lymphoid cells and type 2 immune pathology in vivo
- (2020) Lei Zhang et al. Cellular & Molecular Immunology
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
- (2020) Luis Paz-Ares et al. Journal of Thoracic Oncology
- T cell-engaging therapies — BiTEs and beyond
- (2020) Maria-Elisabeth Goebeler et al. Nature Reviews Clinical Oncology
- Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity
- (2020) Shanling Shen et al. Frontiers in Immunology
- Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
- (2020) Karin M Knudson et al. Journal for ImmunoTherapy of Cancer
- IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
- (2020) Ting Zhou et al. NATURE
- Human immunology and immunotherapy: main achievements and challenges
- (2020) Jezabel Varadé et al. Cellular & Molecular Immunology
- Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses
- (2020) Claire Gorby et al. Science Signaling
- Immunocytokines are a promising immunotherapeutic approach against glioblastoma
- (2020) Tobias Weiss et al. Science Translational Medicine
- Immunopathobiology and therapeutic targets related to cytokines in liver diseases
- (2020) Yong He et al. Cellular & Molecular Immunology
- Tissue-resident lymphocytes: from adaptive to innate immunity
- (2019) Haoyu Sun et al. Cellular & Molecular Immunology
- De novo design of potent and selective mimics of IL-2 and IL-15
- (2019) Daniel-Adriano Silva et al. NATURE
- Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics
- (2019) Jürgen Scheller et al. TRENDS IN IMMUNOLOGY
- Targeting natural killer cells in solid tumors
- (2019) Guillaume Habif et al. Cellular & Molecular Immunology
- Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses
- (2019) Rama Krishna Gurram et al. Cellular & Molecular Immunology
- Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
- (2019) Simona Sivori et al. Cellular & Molecular Immunology
- Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis
- (2019) Jian Qiao et al. CANCER CELL
- A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model
- (2019) Chuanjian Wu et al. Cellular & Molecular Immunology
- Spatial distribution of IL4 controls iNKT cell-DC crosstalk in tumors
- (2019) Lu Wang et al. Cellular & Molecular Immunology
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Killers 2.0: NK cell therapies at the forefront of cancer control
- (2019) Jonathan J. Hodgins et al. JOURNAL OF CLINICAL INVESTIGATION
- Treatment of type 2 diabetes with the designer cytokine IC7Fc
- (2019) Maria Findeisen et al. NATURE
- Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation
- (2019) Patrizia Murer et al. New Biotechnology
- Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
- (2019) Esraa M. Eloseily et al. Arthritis & Rheumatology
- Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages
- (2018) Minwoo Kih et al. BIOMATERIALS
- Potentiation of PD-L1 blockade with a potency-matched dual cytokine–antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains
- (2018) Roberto De Luca et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
- (2018) Benjamin Ribba et al. CLINICAL CANCER RESEARCH
- Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells
- (2018) Kristina S. Burrack et al. IMMUNITY
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Superagonist IL-15-armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
- (2018) Stacy J. Kowalsky et al. MOLECULAR THERAPY
- Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
- (2018) Jonathan T. Sockolosky et al. SCIENCE
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes
- (2018) Ilkka S. Junttila Frontiers in Immunology
- Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
- (2018) Mark R. Albertini et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Checkpoint blockade reverses anergy in IL13Rα2 humanized scFv based CAR T cells to treat murine and canine gliomas.
- (2018) Yibo Yin et al. Molecular Therapy-Oncolytics
- Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
- (2018) Jason M. Redman et al. Journal for ImmunoTherapy of Cancer
- Natural and modified IL-2 for the treatment of cancer and autoimmune diseases
- (2018) Masayuki Mizui CLINICAL IMMUNOLOGY
- ATIM-05. INTRATUMORAL DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, BY MRI-GUIDED CONVECTIVE DELIVERY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA
- (2018) Achal Achrol et al. NEURO-ONCOLOGY
- Modified nanoparticle mediated IL-12 immunogene therapy for colon cancer
- (2017) Xiaoxiao Liu et al. Nanomedicine-Nanotechnology Biology and Medicine
- Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
- (2017) Rodrigo Vazquez-Lombardi et al. Nature Communications
- Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
- (2017) Thomas Shum et al. Cancer Discovery
- Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
- (2017) Jörg U. Schmohl et al. Cancer Research and Treatment
- Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers
- (2017) Ignacio Moraga et al. eLife
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents
- (2016) Sylvia Herter et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions
- (2016) Franziska Bootz et al. DRUG DISCOVERY TODAY
- Blinatumomab: A novel, bispecific, T-cell engaging antibody
- (2015) M. B. May et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Insights into Cytokine–Receptor Interactions from Cytokine Engineering
- (2015) Jamie B. Spangler et al. Annual Review of Immunology
- A targeted IL-15 fusion protein with potent anti-tumor activity
- (2015) Siqi Chen et al. CANCER BIOLOGY & THERAPY
- Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
- (2015) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- IL-15 Superagonist–Mediated Immunotoxicity: Role of NK Cells and IFN-γ
- (2015) Yin Guo et al. JOURNAL OF IMMUNOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Synthetic immunology: modulating the human immune system
- (2015) Barbara Geering et al. TRENDS IN BIOTECHNOLOGY
- CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
- (2014) M. K. Gleason et al. BLOOD
- Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
- (2014) J. Deng et al. CANCER RESEARCH
- The IL-2 cytokine family in cancer immunotherapy
- (2014) Geok Choo Sim et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Side Effects of Cytokines Approved for Therapy
- (2014) Brian A. Baldo DRUG SAFETY
- Preassociation of IL-15 with IL-15R -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action
- (2014) S. Dubois et al. JOURNAL OF IMMUNOLOGY
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Multifaceted Activities of Type I Interferon Are Revealed by a Receptor Antagonist
- (2014) D. Levin et al. Science Signaling
- Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
- (2013) B. Kwong et al. CANCER RESEARCH
- Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
- (2013) W. Xu et al. CANCER RESEARCH
- NK cell-based immunotherapy for malignant diseases
- (2013) Min Cheng et al. Cellular & Molecular Immunology
- Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
- (2013) A. Wiernik et al. CLINICAL CANCER RESEARCH
- Toxicity management for patients receiving novel T-cell engaging therapies
- (2013) David M. Barrett et al. CURRENT OPINION IN PEDIATRICS
- Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
- (2013) Michael Kalos et al. IMMUNITY
- The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+T cells into innate-like effector cells with antitumor activity
- (2013) Hing C Wong et al. OncoImmunology
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
- (2012) H. J. Pegram et al. BLOOD
- IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs
- (2012) J. Emmerich et al. CANCER RESEARCH
- The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel
- (2012) N. Pasche et al. CLINICAL CANCER RESEARCH
- Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours
- (2012) G. Spitaleri et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF
- (2012) Kathrin Schwager et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma
- (2012) Francesco Papadia et al. JOURNAL OF SURGICAL ONCOLOGY
- Manipulation of adenovirus interactions with host factors for gene therapy applications
- (2012) Margaret R Duffy et al. Nanomedicine
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines
- (2012) Ilkka S Junttila et al. Nature Chemical Biology
- Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15
- (2012) Aaron M Ring et al. NATURE IMMUNOLOGY
- IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
- (2011) John B. Mumm et al. CANCER CELL
- Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons
- (2011) Christoph Thomas et al. CELL
- IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
- (2011) Kai-ping Han et al. CYTOKINE
- Gain-of-function mutations ininterleukin-7 receptor-α(IL7R) in childhood acute lymphoblastic leukemias
- (2011) Chen Shochat et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse
- (2011) E. Mezzaroma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells
- (2010) J. J. O'Shea et al. SCIENCE
- The Human Ortholog of Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Fusion Protein Induces Potent Ex vivo Natural Killer Cell Activation and Maturation
- (2009) C. Penafuerte et al. CANCER RESEARCH
- An Engineered GM-CSF-CCL2 Fusokine Is a Potent Inhibitor of CCR2-Driven Inflammation As Demonstrated in a Murine Model of Inflammatory Arthritis
- (2009) M. Rafei et al. JOURNAL OF IMMUNOLOGY
- Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
- (2008) C. Schliemann et al. BLOOD
- The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer
- (2008) K. Wagner et al. CLINICAL CANCER RESEARCH
- IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
- (2008) Nicholas D. Huntington et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More